Raymond Jordt compensation by year
Altimmune Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $405,000 |
| Bonus | $0 |
| Stock awards | $586,125 |
| Option awards | $1,776,009 |
| Non-equity incentive | $162,000 |
| Pension and deferred compensation | $0 |
| All other | $11,850 |
| Total | $2,940,984 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Altimmune, Inc. DEF 14A filed August 15, 2024, accession 0001326190-24-000038, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Altimmune, Inc. filed document, accession 0001326190-24-000038. Every figure is read from that document and cited to the page and table it appears in. Filed August 15, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 37,500 | $421,875 | — |
| Option | 125,000 | — | $15.63 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Altimmune, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
20 Form 4 lines since the FY2023 proxy (filed August 15, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-31 | Grant or award | — | 4,571 | $3.07 | 70,107 |
| 2026-01-27 | Exercise or conversion derivative | — | 15,850 | $0.00 | 47,550 |
| 2026-01-27 | Tax withholding | — | 4,229 | $6.18 | 65,536 |
| 2026-01-27 | Exercise or conversion | — | 15,850 | $0.00 | 69,765 |
| 2026-01-25 | Tax withholding | — | 3,855 | $5.50 | 53,915 |
| 2026-01-25 | Exercise or conversion derivative | — | 14,600 | $0.00 | 29,200 |
| 2026-01-25 | Exercise or conversion | — | 14,600 | $0.00 | 57,770 |
| 2026-01-01 | Tax withholding | — | 2,475 | $3.61 | 43,170 |
The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Altimmune’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Vipin Garg | Chief Executive Officer | $5,482,089 |
| Raymond Jordt · this page | Chief Business Officer | $2,940,984 |
| M. Scott Harris | Chief Medical Officer | $2,239,988 |
The full Altimmune compensation record
free company briefThis page is one person within Altimmune's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Altimmune proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Altimmune's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.